Hengrui Medicine: HRS-3095 tablets receive drug clinical trial approval notification.

Hengrui Pharmaceuticals announced that its subsidiary, Chengdu Shengdi Pharmaceuticals Co., Ltd., has received the approval notice for the clinical trial of HRS-3095 tablets issued by the National Medical Products Administration. The clinical trial will be conducted in the near future. HRS-3095 tablets are a small molecule compound targeting immune cells developed independently by the company, and have shown good therapeutic effects on allergic diseases. Preclinical data have shown that HRS-3095 can effectively improve skin allergy symptoms in mice. According to the investigation, there are currently no approved drugs with the same target for the indication of CSU, both domestically and internationally. As of now, the accumulated research and development investment in the HRS-3095 tablet project is approximately 16.03 million yuan.